Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 18, 2006. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the GlaxoSmithKline Annual Investment Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications.
Material Changes
There are no material changes to financial performance reported in this filing. The document details an increase in share interests for specific individuals following the re-investment of dividends paid on July 6, 2006.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It strictly reports on compliance with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b) regarding director shareholdings.
Important Facts for Investors
- Transaction Type: Increase in Ordinary Shares via dividend re-investment.
- Share Price: GBP 15.15 per share.
- Dividend Date: July 6, 2006.
- Notified Individuals and Share Increases:
- Dr M M Slaoui: 150 shares
- Mr R Bondy: 194 shares
- Mr M Dunoyer: 73 shares
- Mr D Learmouth: 30 shares
- Dr D Pulman: 110 shares
- Mr A Witty: 67 shares